membranous-nephropathy
(2)
Merida Biosciences
Merida Biosciences is a Cambridge, Massachusetts biotechnology company developing a new class of engineered Fc biotherapeutics that selectively bind and eliminate the disease-causing antibodies behind autoimmune and allergic diseases, while sparing the protective antibodies the immune system needs. Launched publicly in April 2025 with a $121 million Series A, the company aims to treat conditions such as Graves' disease, IgE-mediated allergy and primary membranous nephropathy by clearing pathogenic antibodies and suppressing the B cells that make them - without the broad immunosuppression that limits many existing therapies.
GlycoEra AG
GlycoEra AG is a Swiss-American clinical-stage biotech building a new class of precision medicines that selectively degrade the circulating proteins driving autoimmune disease. Spun out of LimmaTech Biologics in 2021 and powered by a proprietary glycoengineering platform, the company designs bifunctional biologics (G-LyTACs) that pull pathogenic autoantibodies out of the bloodstream with speed and depth - without the broad immune suppression of existing therapies. Its lead program, GE8820, targets pathogenic IgG4 autoantibodies. Backed by $179M across Series A and an oversubscribed $130M Series B, GlycoEra operates from Wädenswil, Switzerland and Newton, Massachusetts.